Research Grants
May 2002 . November 2002 . May 2003 . November 2003 . May 2004 . May 2005 . November 2005 . May 2006 . November 2006 . May 2007 . November 2007 . November 2008
12th Grant Competition - November, 2008
| Principal Investigator | Institution | Project Title | Award* |
| Allan, Alison | The University of Western Ontario | Role of ALDH+/CD44+ stem-like cells in breast cancer progression and treatment | $505,578 |
| Berman, Hal K. | University Health Network | Validation of a cellular senescence signature in non-tumoral epithelium as a prognostic biomarker in invasive breast cancer | $120,257 |
| Bjarnason, Georg | Sunnybrook Health Sciences Centre | The impact of gender differences in diurnal proteomics on prognostic indicator development: A proof of concept study in indolent vs. aggressive chronic lymphocytic leukemia patients | $585,129 |
| Bremner, Rod | University Health Network | A Dual Axes Hypothesis for Cancer Initiation and Prevention | $647,913 |
| Bristow, Robert | University Health Network | Genomic Alterations and DNA Repair As Predictors Of Intermediate Risk Prostate Cancer Radiotherapy Outcome | $678,420 |
| Liu, Geoffrey | University Health Network | Pharmacogenetic Companion Study of NCIC-CTG BR.19 Trial | $88,933 |
| Nakatsu, Kanji | Queen's University | Development of Next-Generation Heme Oxygenase Inhibitors as In Vivo Anti-Tumour Agents | $367,197 |
| Siminovitch, Katherine | Mount Sinai Hospital | A new murine model for preclinical studies in prostate cancer | $574,973 |
| Squire, Jeremy | Queen's University | Identification of Functional Interactive Networks Associated with Chemotherapy Resistance and Treatment Failure in Ovarian Cancer by Integrative Molecular Profiling | $522,624 |
| Tabori, Uri | The Hospital for Sick Children | Combined telomerase inhibition and drug screen as novel therapies for tumor initiating cells in pediatric nervous system tumors | $526,153 |
| Trudel, Suzanne | University Health Network | A Companion Study to a Phase II Study of Lenalidomide in Patients with Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL): Identification of Predictive Biomarkers of Response | $484,220 |
| Tsao, Ming-Sound | University Health Network | Novel therapeutic targets for non-small cell lung cancer | $677,548 |
| Zlotta, Alexandre | Mount Sinai Hospital | A proteomic and genetic biomarker panel for improving Prostate Specific Antigen performance and identify individuals at risk of prostate cancer using a unique patient population accrued in the European Randomized Study for Prostate Cancer Screening | $631,233 |
* Includes a value of 30 per cent added for institution overhead.